The objective of this project is to develop the leads which result from the contract effort (N01CM67868) concerned with the screening of compounds for radiosensitizing activity. Analogs of the lead compounds will be synthesized and tested in vitro. The analogs will be developed using the knowledge of the relationship between molecular structure and radiosensitizing effectiveness which has accumulated from past and current studies. New and/or novel radiosensitizers for introduction into the clinic are expected from the proposed project.
| Denny, W A; Wilson, W R; Hay, M P (1996) Recent developments in the design of bioreductive drugs. Br J Cancer Suppl 27:S32-8 |
| Moselen, J W; Hay, M P; Denny, W A et al. (1995) N-[2-(2-methyl-5-nitroimidazolyl)ethyl]-4-(2-nitroimidazolyl)butanamide (NSC 639862), a bisnitroimidazole with enhanced selectivity as a bioreductive drug. Cancer Res 55:574-80 |
| Denny, W A; Atwell, G J; Roberts, P B et al. (1992) Hypoxia-selective antitumor agents. 6. 4-(Alkylamino)nitroquinolines: a new class of hypoxia-selective cytotoxins. J Med Chem 35:4832-41 |
| Wilson, W R; Siim, B G; Denny, W A et al. (1992) 5-Nitro-4-(N,N-dimethylaminopropylamino)quinoline (5-nitraquine), a new DNA-affinic hypoxic cell radiosensitizer and bioreductive agent: comparison with nitracrine. Radiat Res 131:257-65 |
